BNP as discharge criteria for heart failure

Caldwell, Mary A.; Howie, Jill N.; Dracup, Kathleen

doi:10.1054/s1071-9164(03)00124-6

Cited by 9 publications

(8 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The biomarker may be a by-product of the disease state and may also directly participate in its pathogenesis or modulation [ 6 ]. Among cardiovascular biomarkers, brain natriuretic peptide and N - terminal pro-B-type natriuretic peptide (NT-pro-BNP) have emerged as powerful diagnostic tools for acute HF and as screening tools for detecting left ventricular systolic and diastolic dysfunction [ 7 – 10 ]. Several clinical trials have also evaluated the benefit of monitoring BNP and NT-pro-BNP concentrations to guide the therapy and the management of chronic heart failure [ 11 – 13 ].…”

Section: Introductionmentioning

confidence: 99%

A review on B-type natriuretic peptide monitoring: assays and biosensors

Maalouf

Bailey

2016

Heart Fail Rev

View full text Add to dashboard Cite

Since its discovery in 1988, B-type natriuretic peptide (BNP) has been recognized as a powerful cardiovascular biomarker for a number of disease states, specifically heart failure. Concurrent with such a discovery, much effort has been allocated to the precise monitoring of physiological BNP levels. Thus, it can be used to guide the therapy of heart failure and determine the patient’s stage of disease. Thus, we discuss in this article BNP as a potent biomarker. Subsequently, we will review the progress of biosensing devices as they could be applied to monitor BNP levels as assays, benchtop biosensors and implantable biosensors. The analytical characteristics of commercially available BNP assays are presented. Still emerging as a field, we define four obstacles that present opportunity for the future development of implantable biosensor: foreign body response, sensor renewability, sensitivity and selectivity.

show abstract

Section: Introductionmentioning

confidence: 99%

A review on B-type natriuretic peptide monitoring: assays and biosensors

Maalouf

Bailey

2016

Heart Fail Rev

View full text Add to dashboard Cite

show abstract

“…In particular, in patients admitted for acute heart failure, B-type natriuretic peptide levels are reported predicting prognosis in the following 3-6 months: patients with higher pre-discharge values have the worst prognosis, while those with lower or decreased levels with respect to admission have the best prognosis [6], so that B-type natriuretic peptide has been suggested as a discharge criterion [7,8]. Furthermore, on an outsetting basis, it has been shown that a decrease in B-type natriuretic peptide levels is associated to a decrease in event rate for patients managed using the neuro-hormone levels as the target in heart failure therapy [9,10].…”

Section: Introductionmentioning

confidence: 99%

Fall in readmission rate for heart failure after implementation of B-type natriuretic peptide testing for discharge decision: A retrospective study

Valle

Aspromonte

Carbonieri³

et al. 2008

International Journal of Cardiology

View full text Add to dashboard Cite

“…The clinical aspects of proBNP-derived peptides are accordingly frequently and extensively being reviewed (17)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28)(29)(30).…”

mentioning

confidence: 99%

Biochemistry of Pro-B-Type Natriuretic Peptide-Derived Peptides: The Endocrine Heart Revisited

2004

View full text Add to dashboard Cite

Background: Since the discovery of cardiac hormones almost 25 years ago, a vast amount of clinical research has identified the cardiac natriuretic peptides and their precursors as markers of heart failure. It even seems likely that the pro-B-type natriuretic peptide (proBNP)-derived peptides in plasma may become the most frequently measured peptides in the daily diagnosis and control of therapy. In contrast, the biochemistry of the peptides has received less attention. Methods: Published data available on the National Library of Medicine (NLM) were used as the basis for the review. Outcome: This review shows that the present understanding of the biochemistry of peptides is far from complete. In particular, cellular synthesis, including posttranslational precursor maturation, is poorly understood. Moreover, elimination of the precursor fragments is unknown. Elucidation of the molecular heterogeneity of proBNP products will therefore contribute to the understanding of the endocrine heart and may also have important diagnostic consequences. Above all, the different proBNP-derived peptides may not always be equal markers of the same pathophysiologic processes. A different metabolism and peripheral elimination may also impose new and peptide-specific limitations for diagnostic use. Conclusions: It is necessary to focus more on the biology of the proBNP-derived peptides. In turn, new insight into the biochemistry could pave the way for more sensitive and disease-specific assays in the clinical setting.

show abstract

BNP as discharge criteria for heart failure

Cited by 9 publications

References 48 publications

A review on B-type natriuretic peptide monitoring: assays and biosensors

A review on B-type natriuretic peptide monitoring: assays and biosensors

Fall in readmission rate for heart failure after implementation of B-type natriuretic peptide testing for discharge decision: A retrospective study

Biochemistry of Pro-B-Type Natriuretic Peptide-Derived Peptides: The Endocrine Heart Revisited

Contact Info

Product

Resources

About